3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
85
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Leukemia
24
Recurrence
16
Lymphoma
14
Myelodysplastic Syndromes
13
Burkitt Lymphoma
13
Congenital Abnormalities
12
Lymphoma, Non-Hodgkin
10
Leukemia, Monocytic, Acute
10
Leukemia, Myelomonocytic, Acute
8
Leukemia, Erythroblastic, Acute
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia, Megakaryoblastic, Acute
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Myeloproliferative Disorders
5
Lymphoma, Large B-Cell, Diffuse
5
Hodgkin Disease
5
Multiple Myeloma
4
Hematologic Neoplasms
4
Blast Crisis
4
Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell
3
Leukemia, Myelomonocytic, Juvenile
3
Leukemia, Biphenotypic, Acute
3
Anemia, Refractory, with Excess of Blasts
3
Thrombocytopenia
2
Primary Myelofibrosis
2
Neoplasms, Plasma Cell
2
Interventions
eltrombopag
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Jacobs syndrome
×
Cytarabine
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts